MK-8521
Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLCPhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 89/ 100
Competitive context
142 Active assets in the Type 2 Diabetes Mellitus cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Liraglutide RenJi Hospital | Phase 4 | BBB |
Semaglutide Shanghai Jiao Tong University School of Medicine | Phase 4 | BBB |
Exenatide Vivani Medical, Inc | Phase 4 | BBB |
Cotadutide AstraZeneca | Phase 2 | BBB |
Dapagliflozin Bhavya Bhavya, MD | Phase 4 | BBB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →